315 related articles for article (PubMed ID: 27318116)
1. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation.
Arruda LCM; de Azevedo JTC; de Oliveira GLV; Scortegagna GT; Rodrigues ES; Palma PVB; Brum DG; Guerreiro CT; Marques VD; Barreira AA; Covas DT; Simões BP; Voltarelli JC; Oliveira MC; Malmegrim KCR
Clin Immunol; 2016 Aug; 169():47-57. PubMed ID: 27318116
[TBL] [Abstract][Full Text] [Related]
2. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.
Arruda LCM; Malmegrim KCR; Lima-Júnior JR; Clave E; Dias JBE; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Alberdi AJ; Covas DT; Simões BP; Lansiaux P; Toubert A; Oliveira MC
Blood Adv; 2018 Jan; 2(2):126-141. PubMed ID: 29365321
[TBL] [Abstract][Full Text] [Related]
3. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
5. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
[TBL] [Abstract][Full Text] [Related]
6. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity.
Harris KM; Lu T; Lim N; Turka LA
Front Immunol; 2018; 9():100. PubMed ID: 29456529
[TBL] [Abstract][Full Text] [Related]
8. Highly proliferative and functional PD-1
Batorov EV; Aristova TA; Pronkina NV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Shevela EY; Ostanin AA; Chernykh ER
Int Immunopharmacol; 2021 Nov; 100():108093. PubMed ID: 34474273
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.
Darlington PJ; Stopnicki B; Touil T; Doucet JS; Fawaz L; Roberts ME; Boivin MN; Arbour N; Freedman MS; Atkins HL; Bar-Or A
Front Immunol; 2018; 9():834. PubMed ID: 29867923
[TBL] [Abstract][Full Text] [Related]
10. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Ruder J; Rex J; Obahor S; Docampo MJ; Müller AMS; Schanz U; Jelcic I; Martin R
Front Immunol; 2021; 12():794077. PubMed ID: 34975899
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
12. Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis.
Harris KM; Lim N; Lindau P; Robins H; Griffith LM; Nash RA; Turka LA; Muraro PA
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877116
[TBL] [Abstract][Full Text] [Related]
13. CD4
Batorov EV; Tikhonova MA; Kryuchkova IV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Batorova DS; Gilevich AV; Ostanin AA; Shevela EY; Chernykh ER
Int J Hematol; 2017 Jul; 106(1):108-115. PubMed ID: 28293817
[TBL] [Abstract][Full Text] [Related]
14. Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.
Malmegrim KC; de Azevedo JT; Arruda LC; Abreu JR; Couri CE; de Oliveira GL; Palma PV; Scortegagna GT; Stracieri AB; Moraes DA; Dias JB; Pieroni F; Cunha R; Guilherme L; Santos NM; Foss MC; Covas DT; Burt RK; Simões BP; Voltarelli JC; Roep BO; Oliveira MC
Front Immunol; 2017; 8():167. PubMed ID: 28275376
[TBL] [Abstract][Full Text] [Related]
15. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.
Karnell FG; Lin D; Motley S; Duhen T; Lim N; Campbell DJ; Turka LA; Maecker HT; Harris KM
Clin Exp Immunol; 2017 Sep; 189(3):268-278. PubMed ID: 28498568
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
19. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients.
Farge D; Arruda LC; Brigant F; Clave E; Douay C; Marjanovic Z; Deligny C; Maki G; Gluckman E; Toubert A; Moins-Teisserenc H
J Hematol Oncol; 2017 Jan; 10(1):21. PubMed ID: 28103947
[TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
